Literature DB >> 19843027

The 'indirect' effects of cytomegalovirus infection.

R B Freeman1.   

Abstract

Cytomegalovirus (CMV) remains the most important infection in the immunocompromized host even in the era of effective therapy. CMV is usually acquired early in life and can be transmitted by contact with infected body fluids. In the immunocompetent population, primary infection is almost always of little clinical consequence. However, CMV infection in immunocompromized patients, especially those naive to CMV exposure, can cause tissue invasive disease, severe symptoms and/or death. However, beyond these direct effects, increasing in vitro evidence is accumulating that suggests CMV has many other effects on the host's immune response which may explain some of the detrimental consequences for the immunosuppressed patient, and may also be partially responsible for a variety of conditions in immunocompetent individuals. In its latent state, CMV employs several mechanisms to evade detection by the host's immune system. The virus also employs other methods to take advantage of activation of the immune system and replicate in sites of inflammation. This review focuses on the immunosuppressive and inflammatory mechanisms that have been attributed to CMV and will relate them to some of the clinical sequellae that have been associated with the indirect effects of CMV infection.

Entities:  

Mesh:

Year:  2009        PMID: 19843027     DOI: 10.1111/j.1600-6143.2009.02824.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  64 in total

Review 1.  Management of cytomegalovirus infection in solid organ transplantation.

Authors:  Camille N Kotton
Journal:  Nat Rev Nephrol       Date:  2010-10-26       Impact factor: 28.314

Review 2.  The role of the T cell in age-related inflammation.

Authors:  Richard Macaulay; Arne N Akbar; Sian M Henson
Journal:  Age (Dordr)       Date:  2012-01-15

Review 3.  Aging, cytomegalovirus (CMV) and influenza vaccine responses.

Authors:  Daniela Frasca; Bonnie B Blomberg
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

4.  Latent cytomegalovirus infection and innate immune function following a 75 km cycling time trial.

Authors:  Emily C P LaVoy; David C Nieman; Dru A Henson; R Andrew Shanely; Amy M Knab; Lynn Cialdella-Kam; Richard J Simpson
Journal:  Eur J Appl Physiol       Date:  2013-08-09       Impact factor: 3.078

5.  How does cytomegalovirus factor into diseases of aging and vaccine responses, and by what mechanisms?

Authors:  Allison E Aiello; Yen-Ling Chiu; Daniela Frasca
Journal:  Geroscience       Date:  2017-06-18       Impact factor: 7.713

6.  Childhood environments and cytomegalovirus serostatus and reactivation in adults.

Authors:  Denise Janicki-Deverts; Sheldon Cohen; William J Doyle; Anna L Marsland; Jos Bosch
Journal:  Brain Behav Immun       Date:  2014-03-25       Impact factor: 7.217

Review 7.  Inflammaging decreases adaptive and innate immune responses in mice and humans.

Authors:  Daniela Frasca; Bonnie B Blomberg
Journal:  Biogerontology       Date:  2015-04-29       Impact factor: 4.277

8.  Ganciclovir prophylaxis improves late murine cytomegalovirus-induced renal allograft damage.

Authors:  Masako Shimamura; Maria C Seleme; Lingling Guo; Ute Saunders; Trenton R Schoeb; James F George; William J Britt
Journal:  Transplantation       Date:  2013-01-15       Impact factor: 4.939

9.  P-selectin mediates the microvascular dysfunction associated with persistent cytomegalovirus infection in normocholesterolemic and hypercholesterolemic mice.

Authors:  Evgeny Senchenkov; Mikhail V Khoretonenko; Igor L Leskov; Dmitry V Ostanin; Karen Y Stokes
Journal:  Microcirculation       Date:  2011-08       Impact factor: 2.628

10.  Effectiveness of Preemptive Therapy for Cytomegalovirus Disease in Pediatric Liver Transplantation.

Authors:  Emanuele Nicastro; Sara Giovannozzi; Paola Stroppa; Valeria Casotti; Anna Paola Callegaro; Alessandra Tebaldi; Claudio Farina; Michele Colledan; Lorenzo DʼAntiga
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.